about
Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesionsBiomarkers and Algorithms for the Diagnosis of Vitamin B12 DeficiencyPharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo--a systematic reviewManagement of gastric polyps: an endoscopy-based approachEndoscopic Management of Gastroesophageal Reflux Disease: RevisitedLansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer PhenotypeUpper gastrointestinal bleed associated with cholinesterase inhibitor useProton pump induced thrombocytopenia: A case report and review of literature.A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study.Endoscopic Accessories Used for More Advanced Endoluminal Therapeutic ProceduresAssociation between vitamin B12 deficiency and long-term use of acid-lowering agents: a systematic review and meta-analysis.Inhibition of Gastric Acid Secretion by H2 Receptor Antagonists Associates a Definite Risk of Enteric Peritonitis and Infectious Mortality in Patients Treated with Peritoneal Dialysis.Current management of the gastrointestinal complications of systemic sclerosis.Parkinson's disease between internal medicine and neurologyLong-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication ratesLong-term use of proton pump inhibitors and prevalence of disease- and drug-related reasons for gastroprotection-a cross-sectional population-based study.Inflammatory bowel disease, high-dose steroids, osteoporosis, or an oncological etiology for a pathological femoral neck fracture in a young adult: a case report.Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.Proton pump inhibitor is a risk factor for recurrence of common bile duct stones after endoscopic sphincterotomy - propensity score matching analysisGhrelin and bone.Hypomagnesemia and proton-pump inhibitors.Endotherapy for and tailored approaches to treating GERD, and refractory GERD.Antireflux surgery for dysplastic Barrett.Evaluation of acotiamide for the treatment of functional dyspepsia.Common GI Drug Interactions in the Elderly.Cystic fibrosis: An update for clinicians. Part 1: Nutrition and gastrointestinal complications.Acid suppressing therapy as a risk factor for Candida esophagitis.Omeprazole and Semen Quality.Clinical Outcomes of Acid Suppressive Therapy Use in Hematology/Oncology Patients at an Academic Medical Center.A Closer Look at the 2015 Beers Criteria.Proton-pump inhibitor therapy and vitamin B12 status in an inpatient hospital setting.Proton pump inhibitors and statins: a possible interaction that favors low-density lipoprotein cholesterol reduction?GC-MS Analysis and Gastroprotective Evaluations of Crude Extracts, Isolated Saponins, and Essential Oil from Polygonum hydropiper LPharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.From hypomagnesaemia to Zollinger-Ellison syndrome: an adverse effect of a proton pump inhibitor.Impact of clinical pharmacist interventions on inappropriate prophylactic acid suppressant use in hepatobiliary surgical patients undergoing elective operations.The dose of omeprazole required to achieve adequate intraesophageal acid suppression in patients with gastroesophageal junction specialized intestinal metaplasia and Barrett's esophagus.Streptococcus agalactiae meningoencephalitis associated with gastroesophageal reflux disease and chronic proton pump inhibitors use, in a 9 month-old infant: a case report.Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists' effect on prescribing practice at a tertiary hospital.
P2860
Q24187480-037CD3AC-67EC-4F5B-B941-B6B1340FE663Q26742072-DEC4CC9C-590A-4328-A504-68AA9C0DCE12Q26822474-661B06AE-B82E-4206-BBC3-9B9DC03F02EFQ26864650-67D09F27-425B-4602-9282-3CA5796B20FFQ28070037-FF654E29-9C44-4F15-915D-CBA7635BD6C6Q30300235-4FC87B00-72B6-4372-8F2C-9BF2DEE9BDE2Q33166305-B4D7EAE9-581D-457F-8795-379874848998Q33417594-64F6832E-4E21-4CD8-8CFA-2606D9C8E23AQ33441225-181DDFD3-382F-46C9-99AC-C4A28AEBF8D4Q33634843-2F9CA4F6-AF6E-4626-B256-48A83A778F56Q33811372-231792F2-AAAF-4FC5-A133-021F0550413DQ35541947-544ACCA2-26D7-4463-B238-3515000B7BA0Q35922573-8BE22DBD-F099-46ED-A095-E077AE9C74A2Q36068493-30269C08-199B-4A1F-B6B7-0B530184325AQ36464243-1A0B6C04-02DB-4BFA-9CF7-027D04194F16Q37578697-62D63997-889C-4AE4-AAA2-714C68A28514Q37596015-37CE4FBF-80D0-4365-937D-94EF4FB3D838Q37614903-00B9B2CB-DB1C-4ABC-B378-3B842D88537EQ37634917-0318FBF9-DF43-4E05-BAEA-F0884F0F0E54Q37735912-4DBBBED7-529F-45F4-A39B-452CA07FC9F9Q38117311-8F919907-80B6-4DFC-9F4F-22A303C1E9B2Q38117650-61B8C668-7BCD-4637-9615-814639526023Q38151813-E3FBF9F5-B273-4727-8A0D-EC1A54788CF9Q38210074-FC8BE118-4F3A-48F4-9F1A-89FABD1C9517Q38216446-5639118D-4D80-4C78-ADF9-7DC338E1C67BQ38230328-A7DDF67E-4CA9-4B99-9A19-9E108AB17A8DQ38317967-651373C5-8AB7-4999-935D-8AFBDBF96937Q38400673-1672AD03-18AA-4D69-949C-E924ED835DEEQ38634344-598FA52F-8EF0-4644-8681-F12926769ED4Q38811584-E4F30795-5194-468F-91A7-712362B72147Q38947477-98484EA0-2115-4ACF-915D-5743988BD299Q38969006-1E701388-2405-4243-B40D-C0A2EBC7E8AAQ39335694-5D598C64-34F1-4025-8135-106DFFD42C55Q41203467-6A62E67D-452C-43F6-A125-313B492931BDQ41706384-BFE6C2A4-0CE0-41E0-954D-8D9CD4DA3B67Q41719527-0513E0F8-DAB4-4FBB-A278-B27C56C31780Q42680350-46C814F9-49B7-4B45-ADB6-39FB04510C07Q43756856-D103C590-D1F2-4F8D-9E08-37BC7759011DQ47640167-093A757E-8E14-48AF-BA2A-B8A1247599DCQ55693109-83165032-7ADF-49CB-A61B-10666DB01295
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Proton pump inhibitors: potential adverse effects.
@en
type
label
Proton pump inhibitors: potential adverse effects.
@en
prefLabel
Proton pump inhibitors: potential adverse effects.
@en
P1476
Proton pump inhibitors: potential adverse effects.
@en
P2093
Neena S Abraham
P304
P356
10.1097/MOG.0B013E328358D5B9
P577
2012-11-01T00:00:00Z